Japan strengthening biopharma capabilities

Asia’s biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.

Japan, after a period of slowing innovation, is repositioning biopharma as a strategic priority through regulatory reform, pricing policy changes, increased R&D funding, and startup support.

Initiatives spanning regenerative medicine, digital transformation, and AI-driven drug discovery, backed by strong university–industry collaboration and venture funding, are revitalising Japan’s ecosystem and positioning the country to re-emerge as a leading Asian biopharma innovation hub.

Ruplekha Choudhurie, Research Manager, Advanced SciTech, Everest Group and Debarati Sengupta , Research Manager, Advanced SciTech, Everest Group, explained all.

To see the full article, visit: Read here